Search Results
Your search for The matches 34670 pages
Showing 30501 - 30550Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Cancer Will Always Be Part of My Life
My first experience with cancer was when I was just 9 years old, and a lump the size of an egg popped out on the right side of my neck. A biopsy of the tumor found that it was Hodgkin lymphoma, and I was given huge doses of external-beam radiotherapy applied to my neck, chest, and underarm lymph...
Margaret Foti Recognized as 2015 Honoree of the ‘One Hundred’ by Massachusetts General Hospital Cancer Center
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), was honored for her “dedication and commitment to solving cancer through research” and for her “passionate advocacy for increased federal funding for cancer research and biomedical science,” at Massachusetts...
Meir Wetzler, MD, RPCI Leukemia Chief, Dies at Age 60
Meir Wetzler, MD, Chief of the Leukemia Section at Roswell Park Cancer Institute and University at Buffalo (UB) Professor of Medicine, died on February 23 from injuries sustained during a skiing accident in Colorado. He was 60 years old. Nationally prominent in his field, Dr. Wetzler helped set...
Carol A. Kruse, PhD, Pioneer in Brain Cancer Research and Immunotherapy, Dies at Age 61
Carol A. Kruse, PhD, a University of California, Los Angeles (UCLA) scientist and recognized leader in immunologic therapy for brain cancer, recently passed away in Los Angeles after a 6-month battle with an aggressive form of cancer. She was 61. Dr. Kruse was a UCLA Professor of Neurosurgery and...
Alan C. Sartorelli, PhD, Pioneer in Targeted Chemotherapy and AACR Past President, Dies at Age 83
Alan C. Sartorelli, PhD, Alfred Gilman Professor of Pharmacology at Yale University School of Medicine, Past President of the American Association for Cancer Research (AACR), and a Fellow of the AACR Academy, died on April 30, 2015. A pioneer in cancer chemotherapy, Dr. Sartorelli was one of the...
2015 Oncology Meetings
JUNE The International Society of Ocular Oncology (ISOO) MeetingJune 16-19 • Paris, France For more information: http://www.isoo.org 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review...
Martin McMahon, PhD, Joins Research Team at Huntsman Cancer Institute
Martin McMahon, PhD, will join Huntsman Cancer Institute (HCI) at the University of Utah in August 2015 as Professor in the Department of Dermatology and HCI Senior Director of Preclinical Translation. Dr. McMahon is currently the Efim Guzik Distinguished Professor of Cancer Biology at the...
Jonathan L. Finlay, MB, ChB, FRCP, Recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer
During the Wyss Family Symposium, hosted by Nationwide Children’s Hospital May 11–12, Jonathan L. Finlay, MB, ChB, FRCP, Director of Neuro-Oncology at Nationwide Children’s, was announced as the first recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer. Dr. Finlay is...
Mount Sinai Receives $8.8 Million Grant to Further Stem Cell Research
An $8.8 million grant from the New York State Stem Cell Science Program (NYSTEM) will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders. Increasing Stem Cells...
Giving Effective Feedback
Charlene M. Dewey, MD, MEd, FACP, Assistant Dean of Educator Development; Associate Professor of Medical Education and Administration; and Associate Professor of Medicine at Vanderbilt University School of Medicine in Nashville, offers these suggestions for effectively communicating feedback to...
How and When to Give Professional Feedback
Providing students and residents with feedback on their medical performance is a key element in their learning and development and ensures that high standards are met, according to Charlene M. Dewey, MD, MEd, FACP, Assistant Dean of Educator Development; Associate Professor of Medical Education and ...
Five Oncology Researchers Selected as Howard Hughes Medical Institute Investigators
The Howard Hughes Medical Institute announced 26 of the nation’s top biomedical researchers as investigators for the Institute. These scientists will receive the flexible support necessary to move their research in creative new directions. The initiative represents an investment in basic biomedical ...
Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?
The phase III RAISE trial—reported by Tabernero and colleagues in The Lancet Oncology1 and reviewed in this issue of The ASCO Post—demonstrated that ramucirumab (Cyramza), a fully human IgG1 monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR2) extracellular domain, in...
Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer
In the phase III RAISE trial reported in The Lancet Oncology, Josep Tabernero, MD, PhD, Head of Medical Oncology at Vall d’Hebron Institute of Oncology, Barcelona, and colleagues found that the addition of the antiangiogenic anti–vascular endothelial growth factor receptor 2 (VEGFR2) antibody...
Nancy Brinker Named May LUNGevity Hero
The LUNGevity Foundation has announced Nancy Brinker, Founder and Chief of Global Strategy of Susan G. Komen, as the May LUNGevity Hero in recognition of her decades-long dedication and trailblazing work in the fight against cancer. A true pioneer of the advocacy movement, Ms. Brinker gave a...
Daniel D. Von Hoff, MD, FACP, Receives the 2015 Wallace A. Reed, MD, Award
Daniel D. Von Hoff, MD, FACP, Distinguished Professor and Physician-in-Chief of the Translational Genomics Research Institute (TGen), received the 2015 Wallace A. Reed, MD, Award on May 29 from the Arizona Medical Association (ArMA). The award recognizes his accomplishments in advancing innovative...
Roswell Park Cancer Institute Appoints New Leadership Team
Roswell Park Cancer Institute recently announced a restructuring of its leadership. “In many cases, these new appointments represent Roswell Park Cancer Institute parlaying our own existing strengths and talents,” says President and CEO Candace Johnson, PhD. “Restructuring some of these positions...
ASCO 2015—Investigators Announce Patient Enrollment for NCI-MATCH Trial
Investigators for the nationwide trial, NCI-MATCH: Molecular Analysis for Therapy Choice (EAY131), have announced that the precision medicine trial will open to patient enrollment in July. The announcement was made recently during ASCO’s Annual Meeting in Chicago. The MATCH trial seeks to determine ...
Fulfilling NCI’s Commitment to Supporting the Best Science
On April 1, 2015, Douglas R. Lowy, MD, became Acting Director of the National Cancer Institute (NCI), succeeding Harold Varmus, MD, who left NCI to join the faculty of Weill Cornell Medical College in New York. (See “The Next Step in a Storied Career,” in the May 25, 2015 issue of The ASCO Post.)...
ASCO Appoints Lidia Schapira, MD, FASCO, Editor in Chief of Patient Information Website, Cancer.Net
ASCO appointed Lidia Schapira, MD, FASCO, a medical oncologist at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, the new Editor in Chief of its award-winning patient information website, Cancer.Net. Dr. Schapira assumed this role at the...
The Promise of Immune Checkpoint Inhibition: Changing the Therapeutic Landscape for Melanoma and Other Malignancies
The past 3 years have witnessed transformative changes in the way that solid tumors and hematologic malignancies are approached, in almost every instance now including consideration of some form of immunomodulation in the first- or later-line therapeutic setting. The greatest success has occurred...
Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma Progressing After Anti–CTLA-4 Treatment
In a phase III trial (CheckMate 037) reported in The Lancet Oncology, Jeffrey S. Weber, MD, PhD, of the Moffitt Cancer Center, and colleagues found that treatment with the PD-1 (programmed cell death protein 1) inhibitor nivolumab (Opdivo) resulted in a significantly greater response rate vs...
Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman
Kenneth C. Frazier, JD, Chairman and CEO of Merck & Co., Inc., was elected Chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Frazier formerly held the position of Chairman-Elect and succeeds Ian C. Read, Chairman and CEO of Pfizer, Inc. New Officers ...
New ASCO University® Tumor Genomics Program Helps Cancer Care Providers Increase Their Understanding of Next-Generation Sequencing
Innovation in the field of genomic assessment and characterization has rapidly progressed in recent years. As next-generation sequencing increasingly becomes a standard of care, it is vital for cancer care providers to develop a deeper understanding of its research and clinical applications. For...
ASCO’s Community Research Forum Offers Helpful Tools for Community-Based Research Sites
As part of ASCO’s efforts to support research sites and clinical investigators, ASCO’s Community Research Forum (CRF) was created as a solution-oriented venue for community-based research sites. The Forum and its working groups have developed several tools and resources that aim to help researchers ...
Over 30 Organizations, Including ASCO, Call for FDA to Regulate E-Cigarettes
ASCO, together with 30 organizations, have sent a letter to President Obama asking for his leadership in giving the U.S. Food and Drug Administration (FDA) the authority to regulate e-cigarettes and other currently unregulated tobacco products. The 2009 Family Smoking Prevention and Tobacco Control ...
ASCO Launches Electronic Practical Tips for the Oncology Practice, 6th Edition
In mid-May, ASCO launched Practical Tips for the Oncology Practice, 6th Edition, a comprehensive resource providing answers to the most commonly asked questions regarding billing, coding, reimbursements, coverage questions, and regulatory policies that affect the day-to-day practice of oncology....
New ASCO Journal to Focus on Cancer in Resource-Constrained Countries
Internationally renowned oncologist David Kerr, MD, DSc, will serve as founding Editor-in-Chief of the new ASCO publication, Journal of Global Oncology (JGO). JGO will be the first journal focused exclusively on cancer research, treatment, and care delivery in middle- and low-resource countries...
First National Data on Breast Cancer Subtypes Mark New Era in Biomarker Epidemiology
This year’s Report to the Nation on the Status of Cancer contains the first national combined data set on the incidence of four major breast cancer subtypes by race/ethnicity, poverty level, geography, and other factors. The findings show that “there are unique racial/ethnic-specific incidence...
Institute of Medicine to Become National Academy of Medicine
At its 152nd Annual Meeting on April 28, 2015, the membership of the National Academy of Sciences voted to change the name of the Institute of Medicine to the National Academy of Medicine. The newly named National Academy of Medicine will continue to be an honorific society and will inherit the...
Large Urology Group Practice Association Appoints President-Elect
Neal Shore, MD, FACS, of Atlantic Urology Clinics, LLC, was recently appointed President-Elect of the Large Urology Group Practice Association (LUGPA). “I am honored to be appointed to this prestigious position within [the Association] and look forward to furthering the organization’s goal,...
Eduardo M. Sotomayor, MD, Named Director of GW Cancer Center
The George Washington University (GW) School of Medicine and Health Sciences (SMHS), the GW University Hospital, and the GW Medical Faculty Associates announced the appointment of Eduardo M. Sotomayor, MD, as the inaugural Director of the GW Cancer Center (GWCC). He will also serve as a Professor...
The Basket Trial: An Evolving Clinical Trial Design
The recently published results of the CUSTOM (Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies) trial, reviewed in this issue of The ASCO Post, describe a basket trial focused on identifying molecular biomarkers in advanced non–small cell lung cancer (NSCLC), small...
Outcomes of the CUSTOM ‘Basket’ Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies
In the phase II CUSTOM trial reported in the Journal of Clinical Oncology, Ariel Lopez-Chavez, MD, Anish Thomas, MD, and colleagues performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or thymic malignancies and...
What Is the Future of Intraperitoneal Treatment in Advanced Ovarian Cancer?
An analysis of Gynecologic Oncology Group (GOG) studies recently reported in the Journal of Clinical Oncology by Tewari and colleagues and reviewed in this issue of The ASCO Post showed a survival benefit of intraperitoneal chemotherapy vs intravenous chemotherapy over long-term follow-up in women...
Long-Term Survival Advantage Seen With Intraperitoneal vs Intravenous Chemotherapy in Advanced Ovarian Cancer
In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Devansu Tewari, MD, of Kaiser Permanente Irvine Medical Center, and colleagues found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous...
Expert Point of View: Aditya Bardia, MD
These results are promising. The fact that there were two patients with a complete response caught my eye. This is very exciting in metastatic triple-negative breast cancer. These were heavily pretreated patients; 85% had more than four lines of prior therapy,” said Aditya Bardia, MD, a breast...
Anti–PD-L1 Agent Shows Activity in Early Study of Triple-Negative Breast Cancer
An investigational immunotherapy called MPDL3280A showed encouraging and durable clinical activity in heavily pretreated patients with metastatic triple-negative breast cancer, in an early study presented at the 2015 Annual Meeting of the American Association of Cancer Research (AACR).1 Responses...
Studies Evaluate Effectiveness of Active Surveillance in Prostate Cancer Patients
Active surveillance has become a viable option for many men with low-risk prostate cancer who choose not to undergo active treatment such as surgery or radiotherapy. Four studies evaluating the effectiveness, trends, and other considerations for active surveillance in managing prostate cancer were...
New Studies Call for Smarter Approach to Prostate Cancer Screening
Prostate cancer is one of the most common cancers in American men, yet controversy over the utilization and frequency of prostate-specific antigen (PSA) screening methods remains, due to the overdiagnosis and overtreatment of men with low-grade, less-aggressive forms of the disease. At the 110th...
Expert Point of View: Julie A. Margenthaler, MD
Julie A. Margenthaler, MD, of Siteman Cancer Center, St. Louis, who moderated a press briefing at the American Society of Breast Surgeons 16th Annual Meeting, commented on these findings and fielded some questions about the procedure. Dr. Margenthaler indicated that although nipple-sparing...
Nipple-Sparing Mastectomy Shown to Be Oncologically Safe
Mastectomies that preserve the nipple and an envelope of breast skin are as safe as more radical operations for qualifying early-stage breast cancer patients, according to a meta-analysis and systematic literature review presented at the American Society of Breast Surgeons 16th Annual Meeting.1...
Cost Analysis of Bilateral Prophylactic Mastectomy
Bilateral prophylactic mastectomy may ease cancer-related anxiety for patients at high risk of breast cancer, but it does very little to contain the costs. A study presented at the American Society of Breast Surgeons 16th Annual Meeting found that bilateral prophylactic mastectomy was not...
Expert Point of View: Alison M. Friedmann, MD
Commenting on the AREN0532/AREN0533 data, Alison M. Friedmann, MD, of the Department of Hematology/Oncology at Massachusetts General Hospital, Boston, said that this is an important study. “This continues to build on the highly successful risk-adapted treatment approach of the previous National...
Intensified Therapy Improves Survival in Wilms Tumor Patients With Rare Genetic Abnormality
Data from two phase III studies led by the Children’s Oncology Group show that augmenting or intensifying therapy for children with high-risk Wilms tumor improved relapse-free survival. These children are deemed to be at high risk due to a specific chromosomal abnormality that confers worse...
Expert Point of View: Andrew B. Lassman, MD
Formal discussant, Andrew B. Lassman, MD, of the Department of Neurology at Herbert Irving Comprehensive Cancer Center and Columbia University Medical Center in New York, congratulated Dr. Brown and his coauthors for undertaking and completing a “herculean task” that took 10 years. To illustrate...
Whole-Brain Radiation: Risks Outweigh Benefits for Limited Brain Metastases
New data from a phase III Alliance trial weighs in on a longstanding debate in the treatment of brain metastases: Should whole-brain radiation therapy be added to stereotactic radiosurgery? The study found that although whole-brain radiation therapy improved local tumor control in patients with...
Expert Point of View: Lori J. Wirth, MD
Pembrolizumab [Keytruda] has a more favorable side-effect profile than cytotoxic chemotherapy and cetuximab [Erbitux]. This is particularly important for recurrent/metastatic head and neck cancer patients who have been so beaten up by their disease, the treatment for their disease, and their...
Clinically Meaningful Preliminary Results With Pembrolizumab in Recurrent Head and Neck Cancer
Pembrolizumab (Keytruda) is making inroads into head and neck cancer, with encouraging results in heavily pre-treated patients with recurrent or metastatic squamous cell carcinoma of the head and neck, according to a report on the expansion-cohort KEYNOTE-012 study presented at the 2015 ASCO...
